Hepion Pharmaceuticals, Inc.
HEPA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $423 | $22 | -$592 |
| G&A Expenses | $528 | $919 | $1,258 | $1,794 |
| SG&A Expenses | $528 | $919 | $1,258 | $1,794 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $403 | $0 | $0 |
| Operating Expenses | $528 | $1,746 | $1,281 | $1,202 |
| Operating Income | -$528 | -$1,746 | -$1,281 | -$1,202 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $55 | $703 | -$4,825 | -$345 |
| Pre-Tax Income | -$473 | -$1,043 | -$6,106 | -$1,547 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$473 | -$1,043 | -$6,106 | -$1,547 |
| % Margin | – | – | – | – |
| EPS | -0.04 | -0.09 | -2.15 | -11.12 |
| % Growth | 55.6% | 95.8% | 80.7% | – |
| EPS Diluted | -0.04 | -0.09 | -2.15 | -11.12 |
| Weighted Avg Shares Out | 11,620 | 11,328 | 2,837 | 139 |
| Weighted Avg Shares Out Dil | 11,620 | 11,328 | 2,837 | 139 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $8 | $0 | $25 | $818 |
| Depreciation & Amortization | $8 | $8 | $0 | $0 |
| EBITDA | -$457 | -$1,335 | -$6,081 | $3,230 |
| % Margin | – | – | – | – |